Quantitative analysis of 18F-(E)-N-(3-iodoprop-2-enyl)-2β-carbofluoroethoxy-3β-(4'-methyl-phenyl) nortropane binding to the dopamine transporter in Parkinson disease

Journal of Nuclear Medicine

Volumn 56, Issue 5, 2015, Pages 714-720

  Fazio, Patrik ^a   Svenningsson, Per ^a   Forsberg, Anton ^a   Jönsson, Erik G ^a,b   Amini, Nahid ^a   Nakao, Ryuji ^a   Nag, Sangram ^a   Halldin, Christer ^a   Farde, Lars ^a   Varrone, Andrea ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Dopamine transporter; Nigra; Parkinson disease; PET; Substantia

Indexed keywords

DOPAMINE TRANSPORTER; N (3 IODOPROP 2 ENYL) 2BETA CARBOFLUOROETHOXY 3BETA (4' METHYLPHENYL)NORTROPANE 18 F; RADIOLIGAND; UNCLASSIFIED DRUG; (E)-N-(3-IODOPROP-2-ENYL)-2BETA-CARBOFLUOROETHOXY-3BETA-(4'-METHYL-PHENYL) NORTROPANE; NORTROPANE DERIVATIVE; PROTEIN BINDING;

ADULT; AGED; ARTICLE; BIOCHEMICAL COMPOSITION; BLOOD LEVEL; BRAIN REGION; CAUDATE NUCLEUS; CEREBELLUM; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; FEMALE; HUMAN; IN VIVO STUDY; MALE; MIDDLE AGED; MINI MENTAL STATE EXAMINATION; NIGRONEOSTRIATAL SYSTEM; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BINDING; PUTAMEN; QUANTITATIVE ANALYSIS; RADIOACTIVITY; SUBSTANTIA NIGRA; UNIFIED PARKINSON DISEASE RATING SCALE; VENTRAL STRIATUM; DIAGNOSTIC USE; METABOLISM; SCINTISCANNING;

AGED; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; MALE; MIDDLE AGED; NORTROPANES; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; SUBSTANTIA NIGRA;

EID: 84929484781     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.114.152421     Document Type: Article

References (35)

1. Hersch SM, Hong YI, Heilman CJ, Edwards RH, Levey AI. Subcellular localization and molecular topology of the dopamine transporter in the striatum and substantia nigra. J Comp Neurol. 1997;388:211-227.
2. Nirenberg MJ, Vaughan RA, Uhl GR, Kuhar MJ, Pickel VM. The dopamine transporter is localized to dendritic and axonal plasma membranes of nigrostriatal dopaminergic neurons. J Neurosci. 1996;16:436-447.
3. Vaughan RA, Foster JD. Mechanisms of dopamine transporter regulation in normal and disease states. Trends Pharmacol Sci. 2013;34:489-496.
4. 123I]beta-CIT. Biol Psychiatry. 2000;47:371-379.
5. 123I]beta-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy. Mov Disord. 2001;16:1023-1032.
6. Walker Z, Costa DC, Walker RW, et al. Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease: a comparison. Neurology. 2004;62:1568-1572.
7. Stiasny-Kolster K, Doerr Y, Moller JC, et al. Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alphasynucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain. 2005;128:126-137.
8. Scherfler C, Khan NL, Pavese N, et al. Striatal and cortical pre- and postsynaptic dopaminergic dysfunction in sporadic parkin-linked parkinsonism. Brain. 2004;127:1332-1342.
9. Cummings JL, Henchcliffe C, Schaier S, Simuni T, Waxman A, Kemp P. The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration. Brain. 2011;134:3146-3166.
10. Antonini A, Biundo R. Can dopamine transporter imaging define early PD? Nat. Rev. Neurol. 2014;10:432-433.
11. Ng J, Zhen J, Meyer E, et al. Dopamine transporter deficiency syndrome: phenotypic spectrum from infancy to adulthood. Brain. 2014;137:1107-1119.
12. Seidel K, Mahlke J, Siswanto S, et al. The brainstem pathologies of Parkinson's disease and dementia with Lewy bodies. Brain Pathol. 2015;25:121-135.
13. Lee FJ, Liu F, Pristupa ZB, Niznik HB. Direct binding and functional coupling of α-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. FASEB J. 2001;15:916-926.
14. Oaks AW, Sidhu A. Synuclein modulation of monoamine transporters. FEBS Lett. 2011;585:1001-1006.
15. Kovacs GG, Milenkovic IJ, Preusser M, Budka H. Nigral burden of alphasynuclein correlates with striatal dopamine deficit. Mov Disord. 2008;23:1608-1612.
16. Varrone A, Halldin C. New developments of dopaminergic imaging in Parkinson's disease. Q J Nucl Med Mol Imaging. 2012;56:68-82.
17. 18F]FE-PE2I, a new probe for the dopamine transporter. Bioorg Med Chem Lett. 2009;19:4843-4845.
18. 18F]FE-PE2I, a new dopamine transporter PET radioligand. Synapse. 2009;63:871-880.
19. 18F-FE-PE2I. J Nucl Med. 2011;52:132-139.
20. 18F-FE-PE2I in nonhuman primates: prediction for human studies. Nucl Med Biol. 2012;39:295-303.
21. 18F-FE-PE2I. J Nucl Med. 2012;53:1065-1073.
22. 18F]FE-PE2I in humans. Nucl Med Commun. 2014;35:231-237.
23. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry. 1988;51:745-752.
24. First MB, Spitzer RL, Gibbon M, Williams J. Structured Clinical Interview for DSM-IV Axis I Disorders, Clinician Version (SCID-CV). Washington, D.C.: American Psychiatric Press; 1996.
25. 18F]FE-PE2I, a PET radioligand for imaging of dopamine transporters. J Labelled Comp Radiopharm. 2012;55:206-210.
26. 2C receptors in the nonhuman primate brain. Neuroimage. 2014;84:342-353.
27. Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage. 1996;4:153-158.
28. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996;16:834-840.
29. 11C]WAY 100635. Neuroimage. 2006;32:1690-1708.
30. Schain M, Tóth M, Cselényi Z, et al. Improved mapping and quantification of serotonin transporter availability in the human brainstem with the HRRT. Eur J Nucl Med Mol Imaging. 2013;40:228-237.
31. 11C-PBR28. Anal Bioanal Chem. 2013;405:1303-1310.
32. 125CI]RTI-121. Synapse. 1995;21:364-372.
33. 11C] PE2I. Eur J Nucl Med Mol Imaging. 2007;34:667-678.
34. Cheng HC, Ulane CM, Burke RE. Clinical progression in Parkinson disease and the neurobiology of axons. Ann Neurol. 2010;67:715-725.
35. 18F-DTBZ positron emission tomography. JAMA Neurol. 2014;71:758-766.